Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study.
Cohen, Jeffrey A
Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. [electronic resource] - Journal of neurology, neurosurgery, and psychiatry May 2016 - 468-75 p. digital
Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
1468-330X
10.1136/jnnp-2015-310597 doi
Adult
Disability Evaluation
Double-Blind Method
Female
Fingolimod Hydrochloride--therapeutic use
Humans
Immunosuppressive Agents--therapeutic use
Interferon beta-1a--therapeutic use
Magnetic Resonance Imaging
Male
Multiple Sclerosis, Relapsing-Remitting--drug therapy
Neuroimaging
Recurrence
Treatment Outcome
Young Adult
Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. [electronic resource] - Journal of neurology, neurosurgery, and psychiatry May 2016 - 468-75 p. digital
Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
1468-330X
10.1136/jnnp-2015-310597 doi
Adult
Disability Evaluation
Double-Blind Method
Female
Fingolimod Hydrochloride--therapeutic use
Humans
Immunosuppressive Agents--therapeutic use
Interferon beta-1a--therapeutic use
Magnetic Resonance Imaging
Male
Multiple Sclerosis, Relapsing-Remitting--drug therapy
Neuroimaging
Recurrence
Treatment Outcome
Young Adult